Erypeg 30 Injection

Erypeg 30 Injection is administered via subcutaneous or intravenous routes under medical supervision, with dosage individualized based on patient response and hemoglobin levels. It is indicated to reduce the need for blood transfusions by promoting endogenous erythropoiesis. Prior to initiation, patients should be evaluated for iron status, as adequate iron stores are essential for optimal therapeutic response.

Monitoring of hemoglobin concentration, blood pressure, and potential adverse effects such as hypertension, thromboembolic events, and hypersensitivity reactions is critical during treatment. Erypeg 30 Injection should be used cautiously in patients with uncontrolled hypertension or a history of stroke or cardiovascular disease. This product is contraindicated in patients with hypersensitivity to erythropoietin or any component of the formulation.

Proper storage and handling are required to maintain stability and efficacy.